ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "rheumatoid arthritis (RA) and tumor necrosis factor (TNF)"

  • Abstract Number: 1008 • 2018 ACR/ARHP Annual Meeting

    Presence of a Specific Defect in M2 Polarization of Blood Monocytes from Patients with Rheumatoid Arthritis, Associated with Increased microRNA-155

    Audrey Paoletti1, Julien Rohmer2, Juliette Pascaud3, Bineta Oumouly1, Elodie Rivière3, Samuel Bitoun4, Gaetane Nocturne5 and Xavier Mariette6, 1U1184 IMVA, INSERM U1184, IMVA, Paris Sud University,LabEx LERMIT, le kremlin bicetre, France, 2National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, Internal medicine, France, Paris, France, 3Immunology of viral Infections and Autoimmune Diseases, IDMIT, CEA - Université Paris Sud - INSERM U1184, Le Kremlin Bicêtre & Fontenay aux Roses, France, 4INSERM U1184, IMVA, Paris Sud University,LabEx LERMIT, le kremlin bicetre, France, 5INSERM U1184, IMVA, Paris Sud University,LabEx LERMIT, Le Kremlin Bicêtre, France, 6Rheumatology department, Center for Immunology of Viral Infections and Autoimmune Diseases, Assistance Publique- Hôpitaux de Paris, Hôpitaux Universitaires Paris-Sud, Le Kremlin-Bicêtre, Université Paris Sud, INSERM, Paris, Paris, France

    Background/Purpose: Macrophages contribute in situ to the RA pathogenesis. Two distinct states of polarization for macrophages have been recognized: the classically activated macrophage phenotype (M1),…
  • Abstract Number: 1052 • 2018 ACR/ARHP Annual Meeting

    Detection of Precursors of RANK- Osteoclast-like Cells (Olcs) in Peripheral Blood and Olcs in Bone Tissue from Rheumatoid Arthritis Patients

    Kazuhiro Yokota1, Shinya Tanaka2, Miyoko Sekikawa2, Yoshimi Aizaki1, Kojiro Sato1, Hiromi Oda2 and Toshihide Mimura1, 1Department of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University, Saitama, Japan, 2Department of Orthopaedic Surgery, Saitama Medical University, Saitama, Japan

    Background/Purpose: Proinflammatory cytokines play an important role in bone destruction in rheumatoid arthritis (RA), as inferred by the efficacy of biologics. Previously, we reported that…
  • Abstract Number: 1192 • 2018 ACR/ARHP Annual Meeting

    The Impact of Participation in an Adalimumab (Humira) Patient Support Program on the Onset and Management of Disease Flares

    Filip van Den Bosch1, Siegfried Wassenberg2, Boulos Haraoui3, Patrick Zueger4, Meijing Wu4, Ivan Lagunes Galindo4 and Andrew Ostor5, 1Ghent University Hospital, Ghent, Belgium, 2Rheumazentrum Ratingen, Ratingen, Germany, 3Université de Montréal, Montreal, QC, Canada, 4AbbVie Inc., North Chicago, IL, 5Cabrini Medical Center, Melbourne, Australia

    Background/Purpose: The AbbVie patient (pt) support program (PSP) is offered to pts prescribed adalimumab for RA and other indications. The purpose of this analysis was…
  • Abstract Number: 1522 • 2018 ACR/ARHP Annual Meeting

    Time Dependent Effect of Biologic Therapy on Overall Survival in Patients with Rheumatoid Arthritis and Cancer

    Xerxes Pundole1, Natalia Zamora2, Harish Siddhanamatha3, Jean Tayar4, Cheuk Hong Leung5, Heather Lin6 and Maria Suarez-Almazor7, 1Section of Rheumatology and Clinical Immunology, Department of General Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA, Houston, TX, 2Reumatologia, Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, Buenos Aires, Argentina, 3The University of Texas Health Science Center, School of Biomedical Informatics, Houston, TX, USA, Houston, TX, 4Department of General Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA, Section of Rheumatology and Clinical Immunology, Department of General Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA, Houston, TX, 5Department of Biostatistics, Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA, Houston, TX, 6Biostatistics, Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA, Houston, TX, 7Section of Rheumatology and Clinical Immunology, Department of General Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

    Background/Purpose: Biologic disease-modifying anti-rheumatic drugs (bDMARDs) are commonly used in the treatment of rheumatoid arthritis (RA). But the use of bDMARDs in patients with RA…
  • Abstract Number: 1528 • 2018 ACR/ARHP Annual Meeting

    Unique Changes in Hemoglobin with Sarilumab Versus Adalimumab Are Independent of Better Disease Control in Patients with Rheumatoid Arthritis (RA)

    Gerd R. Burmester1, Owen Hagino2, Qunming Dong3, Marina Stanislav4, Antonio Gomez-Centeno5, Carlo Selmi6, Tom W.J. Huizinga7, Erin Mangan8, Cem Gabay9 and Mark C. Genovese10, 1Charité – University Medicine Berlin, Free University and Humboldt University Berlin, Berlin, Germany, 2Sanofi Genzyme, Bridgewater, NJ, 3Sanofi, Bridgewater, NJ, 4Scientific Research Institute of Rheumatology, Russian Academy of Medical Sciences, Moscow, Russian Federation, 5Corporació Sanitària Parc Taulí, Barcelona, Spain, 6Rheumatology and Clinical Immunology Unit, Humanitas Research Hospital, Rozzano (MI), Italy, 7Leiden University Medical Center, Leiden, Netherlands, 8Regeneron Pharmaceuticals, Inc., Tarrytown, NY, 9University Hospitals of Geneva, Geneva, Switzerland, 10Stanford University Medical Center, Palo Alto, CA

    Background/Purpose: Anemia (WHO criteria: Hemoglobin [Hb] levels <12.0 g/dL [females] or <13.0 g/dL [males]) is a common finding associated with increased joint inflammation in patients…
  • Abstract Number: 2188 • 2018 ACR/ARHP Annual Meeting

    Regional Analysis of Impact of Participation in a Patient Support Program on Clinical Outcomes Among Patients with Rheumatoid Arthritis Receiving Adalimumab (Humira)

    Filip van Den Bosch1, Andrew Ostor2, Patrick Zueger3, Meijing Wu3, Ivan Lagunes Galindo3 and Siegfried Wassenberg4, 1Ghent University Hospital, Ghent, Belgium, 2Cabrini Medical Center, Melbourne, Australia, 3AbbVie Inc., North Chicago, IL, 4Rheumazentrum Ratingen, Ratingen, Germany

    Background/Purpose: Patients (pts) receiving adalimumab for RA or other indications are offered participation in the AbbVie pt support program (PSP). This analysis assessed clinical outcomes…
  • Abstract Number: 2331 • 2018 ACR/ARHP Annual Meeting

    Obesity Might Positively Affect TNF Mediated Bone Metabolism in RA Patients

    Mie Jin Lim1, Won Park2, Seong Ryul Kwon3, Kyong-Hee Jung4 and Seung Yun Lee3, 1Division of Rheumatology, Departments of Internal Medicine, Inha University Hospital, Incheon, Korea, Republic of (South), 2Medicine/Rheumatology, Inha University Hospital, Incheon, Korea, Republic of (South), 3Division of Rheumatology, Department of Internal Medicine, Inha University Hospital, Incheon, Korea, Republic of (South), 4Rheumatology, Inha University Hospital, Incheon, Korea, Republic of (South)

    Background/Purpose: In this study, we tried to find out the effect of obesity on bone metabolism after one year of anti-TNF agent use. Methods:  Thirty-two…
  • Abstract Number: 2595 • 2018 ACR/ARHP Annual Meeting

    Golimumab Improves Socio- and Health Economic Parameters in Patients with RA, Psa and As: Real World-Data from a Non-Interventional Clinical Study in Germany

    Klaus Krüger1, Gerd R. Burmester2, Siegfried Wassenberg3, Valeria Biermann4 and Matthias H. Thomas5, 1Medical Centre of Rheumatology, Munich, Germany, 2Rheumatology and Clinical Immunology, Charité-University Medicine Berlin, Berlin, Germany, 3Rheumazentrum Ratingen, Ratingen, Germany, 4Lehrstuhl für Gesundheitsmanagement, Universität Erlangen-Nürnberg, Nürnberg, Germany, 5Medical Affairs, MSD Sharp & Dohme GmbH, Haar, Germany

    Background/Purpose: Golimumab (GLM) has shown its efficacy and safety in various clinical trials. Data from socio- and health economic parameters and costs in daily clinical…
  • Abstract Number: 2820 • 2018 ACR/ARHP Annual Meeting

    Sustained Clinical Remission after Discontinuation of Infliximab with a Raising Dose Strategy in Patients with Rheumatoid Arthritis (RRRR study): A Randomized Controlled Trial

    Yoshiya Tanaka1, Koji Oba2,3, Takao Koike4,5, Nobuyuki Miyasaka6, Tsuneyo Mimori7, Tsutomu Takeuchi8, Shintaro Hirata9, Eiichi Tanaka10, Hidekata Yasuoka11, Yuko Kaneko8, Kosaku Murakami7, Tomohiro Koga12, Kazuhisa Nakano13, Koichi Amano14, Kazuyasu Ushio15, Tatsuya Atsumi16, Masayuki Inoo17, Kazuhiro Hatta18, Shinichi Mizuki19, Shohei Nagaoka20, Shinichiro Tsunoda21, Hiroaki Dobashi22, Nao Horie3 and Norihiro Sato3, 1University of Occupational and Environmental Health, Kitakyushu, Japan, 2Interfaculty Initiative in Information Studies, The University of Tokyo, Tokyo, Japan, 3Clinical Research and Medical Innovation Center, Hokkaido University Hospital, Sapporo, Japan, 4Hokkaido Medical Center for Rheumatic Diseases, Sapporo, Japan, 5NTT Sapporo Medical Center, Sapporo, Japan, 6Department of Medicine and Rheumatology, Tokyo Medical and Dental University, Tokyo, Japan, 7Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan, 8Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, 9Department of Clinical Immunology and Rheumatology, Hiroshima University Hospital, Hiroshima, Japan, 10Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, 11Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, tokyo, Japan, 12Center for Bioinformatics and Molecular Medicine, Nagasaki University, Graduate School of Biomedical Sciences, Nagasaki, Japan, 13The First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan, 14Department of Rheumatology and Clinical Immunology, Saitama Medical Center, Saitama Medical University, Saitama, Japan, 15Ushio Clinic, Osaka, Japan, 16Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan, 17Utazu hospital, Utatsu-cho, Japan, 18Department of General Medicine, Tenri Hospital, Tenri, Japan, 19Center for Rheumatic Diseases, Matsuyama Red Cross Hospital, Matsuyama, Japan, 20Department of Rheumatology, Yokohama Minami Kyosai Hospital, Yokohama, Japan, 21Division of Rheumatology Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya, Japan, 22Division of Endocrinology and Metabolism, Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Kagawa University, Miki-cho, Japan

    Background/Purpose: Infliximab (IFX), a TNF inhibitor, is one of the most widely used biological disease-modifying antirheumatic drugs. Recent studies indicated that baseline levels of serum…
  • Abstract Number: 1942 • 2017 ACR/ARHP Annual Meeting

    CTLA4-Ig Directly Inhibits Osteoclast Generation from Human Peripheral Monocytes and Tumor Necrosis Factor α-Treated Inflammatory Monocytes

    Katsuhiro Oi1, Tadahiro Tokunaga1, Tatsuomi Kuranobu1, Yusuke Yoshida2, Shintaro Hirata1, Takaki Nojima3 and Eiji Sugiyama2, 1Clinical Immunology and Rheumatology, Hiroshima University Hospital, Hiroshima, Japan, 2Department of Clinical Immunology and Rheumatology, Hiroshima University Hospital, Hiroshima, Japan, 3Clinical Immunology and Rheumatolog, Graduate School of Medicine, Kyoto University, Kyoto, Japan

    Background/Purpose: CTLA-4 is a surface protein on T lymphocytes, which negatively regulates the co-stimulation process between antigen-presenting cells and T cells. CTLA-4 binds to monocytes…
  • Abstract Number: 2024 • 2017 ACR/ARHP Annual Meeting

    Prediction of Response to Certolizumab-Pegol in Rheumatoid Arthritis By Functional MRI of the Brain – an Interim Analysis of an Ongoing Investigator Initiated Phase III Trial

    Hannah Schenker1, Andreas Hess2, Laura Konerth2, Marina Sergeeva2, Jutta Prade2, Arnd Kleyer1, Michaela Reiser1, Axel J. Hueber1, Matthias Englbrecht1, Eugen Feist3, Reinhard Voll4, Bettina Bannert4, C Baerwald5, Julie Rösch6, Arnd Dörfler7, José António P. da Silva8, Nemanja Damjanov9, Georg Schett1 and Juergen Rech1, 1Department of Medicine 3, Rheumatology and Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, 2Institute of Pharmacology and Toxicology, University of Erlangen-Nuremberg, Erlangen, Germany, 3Department of Rheumatology and Clinical Immunology, Charité, Berlin, Berlin, Germany, 4Clinic for Rheumatology and Clinical Immunology, Medical University of Freiburg, Germany, Freiburg, Germany, 5Department of Rheumatology, University of Leipzig, Germany, Leipzig, Germany, 6Department of Neuroradiology, University of Erlangen-Nuremberg, Germany, Erlangen, Germany, 7Department of Neuroradiology, University of Erlangen-Nuremberg, Germany, e, Germany, 8Rheumatology, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal, 9Institute of Rheumatology, Belgrade University School of Medicine, Belgrade, Serbia

    Background/Purpose: Tumor necrosis factor inhibitors (TNFi) signify a major advance in the treatment of rheumatoid arthritis (RA). However, treatment success initially remains uncertain as one…
  • Abstract Number: 2448 • 2017 ACR/ARHP Annual Meeting

    Increased Cumulative Exposure to Tumor Necrosis Factor Inhibitors Reduces Radiographic Progression in US Veterans with Rheumatoid Arthritis in Real World Clinical Practice

    Grant Cannon1, Alan R. Erickson2, Chia-Chen Teng, MS1, Tina Huynh1, Sally W. Wade3, Bradley S. Stolshek4, David Collier5, Alex Mutebi6 and Brian C. Sauer, PhD1, 1Salt Lake City VA Medical Center and University of Utah, Salt Lake City, UT, 2Omaha VA Medical Center and University of Nebraska Medical Center, Omaha, NE, 3Wade Outcomes Research and Consulting, Salt Lake City, UT, 4Amgen, Inc., Thousand Oaks, CA, 5Amgen Inc., Thousand Oaks, CA, 6Global Health Economics, Amgen Inc., Thousand Oaks, CA

    Background/Purpose:    While tumor necrosis factor inhibitors (TNFi) have been proven to reduce progression of structural joint damage in rheumatoid arthritis (RA) in randomized clinical…
  • Abstract Number: 2450 • 2017 ACR/ARHP Annual Meeting

    Comparative Effectiveness of Abatacept Versus TNFi in Patients with RA Who Are CCP+ in the United States Corrona Registry

    Leslie R Harrold1, Heather J. Litman2, SE Connolly3, E Alemao3, K Price3, S Kelly3, Sabrina Rebello4, W Hua2 and Joel Kremer5, 1University of Massachusetts, Worcester, MA, 2Corrona, Southborough, MA, 3Bristol-Myers Squibb, Princeton, NJ, 4Corrona, LLC, Southborough, MA, 5Albany Medical College and The Center for Rheumatology, Albany, NY

    Background/Purpose: Anti-cyclic citrullinated peptide positivity (CCP+) is associated with a better response to abatacept than anti-CCP negativity in patients with RA1,2; however, there are no…
  • Abstract Number: 2485 • 2017 ACR/ARHP Annual Meeting

    Outcomes of Switching from TNF Inhibitors to Subcutaneous Golimumab in Patients with Rheumatoid Arthritis to Control Disease Activity or Adverse Events

    Hiroki Wakabayashi1, Hitoshi Inada2, Yosuke Nishioka3, Masahiro Hasegawa1,4, Kusuki Nishioka5 and Akihiro Sudo6, 1Department of Orthopaedic Surgery, Mie University Graduate School of Medicine, Tsu City, Mie, Japan, 2Orthopaedic Surgery, Suzuka General Hospital, Suzuka, Japan, 3Clinical Research Institute for Rheumatic Disease, Shima, Japan, 4Mie University Graduate School of Medicine, Tsu, Japan, 5Tokyo Medical University, Shinjuku, Japan, 6Department of Orthopaedic Surgery, Mie University Graduate School of Medicine, Tsu City, Japan

    Background/Purpose: Tumor necrosis factor alpha (TNFα) inhibitors have been used to treat rheumatoid arthritis (RA) for >10 years. The outcomes has revolutionized the treatment goal…
  • Abstract Number: 75 • 2017 ACR/ARHP Annual Meeting

    Factors Associated with TNF Receptor 2 Levels Above the Measurable Range in Rheumatoid Arthritis

    Michelle Frits1, Gary Bradwin2, Nancy A. Shadick1, Christine Iannaccone3, Michael Weinblatt1, Nader Rifai2 and Katherine P. Liao4, 1Rheumatology, Immunology and Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 2Laboratory Medicine, Childrens Hospital Boston, Boston, MA, 3Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, 4Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA

    Background/Purpose: Tumor necrosis factor-alpha (TNFa) is involved in the pathogenesis of RA and is increasingly being studied as a biomarker of cardiovascular disease (CVD).  While…
  • 1
  • 2
  • 3
  • …
  • 6
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology